Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial

BACKGROUND: Microsatellite stable (MSS) and RAS-mutant metastatic colorectal cancer (mCRC) patients are characterized by an immunosuppressive microenvironment and a low response rate to immunotherapy. Chemotherapy and anti-angiogenesis therapy have been reported to potentially promote immunotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Xuefeng, Zhu, Ning, Zhong, Chenhan, Wang, Liuhong, Li, Jun, Weng, Shanshan, Hu, Hanguang, Dong, Caixia, Li, Dan, Song, Yongmao, Xu, Dong, Wang, Jianwei, Sun, Lifeng, Wang, Jian, Wang, Zhanhuai, Cao, Hongfeng, Liao, Xiujun, Yu, Ningjuan, Xiao, Qian, Mi, Mi, Zhang, Suzhan, Ding, Kefeng, Yuan, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404864/
https://www.ncbi.nlm.nih.gov/pubmed/37554125
http://dx.doi.org/10.1016/j.eclinm.2023.102123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404864/
https://www.ncbi.nlm.nih.gov/pubmed/37554125
http://dx.doi.org/10.1016/j.eclinm.2023.102123

Ejemplares similares